1.0Allphase Pharma Consulting, LLChttps://allphasepharma.com/dirHaraldhttps://allphasepharma.com/dir/author/haraldeva/Is the AOM Indication Making a Come-Back? - Allphase Pharma Consulting, LLCrich600338<blockquote class="wp-embedded-content" data-secret="sVg8KD3Si4"><a href="https://allphasepharma.com/dir/2017/01/18/3032/indication-aom-making-come-back/">Is the AOM Indication Making a Come-Back?</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://allphasepharma.com/dir/2017/01/18/3032/indication-aom-making-come-back/embed/#?secret=sVg8KD3Si4" width="600" height="338" title="“Is the AOM Indication Making a Come-Back?” — Allphase Pharma Consulting, LLC" data-secret="sVg8KD3Si4" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://allphasepharma.com/dir/wp-includes/js/wp-embed.min.js
</script>
https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2017/01/AOM-slider.jpg?fit=640%2C180&ssl=1640180We will get to the new Hoberman study[1] in a moment, but first a bit of background. AOM, AECS and AECB were labeled indications for antibiotics in the 80s and 90s but were summarily thrown out from the indication catalogue shortly after the 1998 FDA Guidelines were published. The arguments Continue reading →